drugset / Trial / NCT06503224
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
Recruiting
18 enrolled
The First Affiliated Hospital of University of Science and Technology of China
NaSequentialOpen-labelTreatment
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Timeline
- Start
- 2024-04-09
- Primary completion
- 2026-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCAR02 | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | SCAR02 | Cell therapy | 3 cells/kg | Intravenous |